Effects of a SARS-associated coronavirus vaccine in monkeys

Wentao Gao; Azaibi Tamin; Adam Soloff; Leonardo D'Aiuto; Edward Nwanegbo; Paul D. Robbins; William J. Bellini; Simon Barratt-Boyes; Andrea Gambotto

doi:10.1016/S0140-6736(03)14962-8

Effects of a SARS-associated coronavirus vaccine in monkeys

Wentao Gao
, Azaibi Tamin
, Adam Soloff
, Leonardo D'Aiuto
, Edward Nwanegbo
, Paul D. Robbins
, William J. Bellini
, Simon Barratt-Boyes
, Andrea Gambotto

Research output: Contribution to journal › Article › peer-review

259 Scopus citations

Abstract

The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.

Original language	English (US)
Pages (from-to)	1895-1896
Number of pages	2
Journal	Lancet
Volume	362
Issue number	9399
DOIs	https://doi.org/10.1016/S0140-6736(03)14962-8
State	Published - Dec 6 2003
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported by National Heart Lung and Blood Institute, Program of Excellence in Gene Therapy supplement Grants U01 HL66949–01S1 to A Gambotto. The authors thank K Okada and H Sun for assistance with adenoviral preparation. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in the writing of the report.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1016/S0140-6736(03)14962-8

Find It

Find It at U of M Libraries

Cite this

@article{862af20efdcd403da59f3383a6aa7fa6,

title = "Effects of a SARS-associated coronavirus vaccine in monkeys",

abstract = "The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.",

author = "Wentao Gao and Azaibi Tamin and Adam Soloff and Leonardo D'Aiuto and Edward Nwanegbo and Robbins, \{Paul D.\} and Bellini, \{William J.\} and Simon Barratt-Boyes and Andrea Gambotto",

note = "Funding Information: This work was supported by National Heart Lung and Blood Institute, Program of Excellence in Gene Therapy supplement Grants U01 HL66949–01S1 to A Gambotto. The authors thank K Okada and H Sun for assistance with adenoviral preparation. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in the writing of the report. ",

year = "2003",

month = dec,

day = "6",

doi = "10.1016/S0140-6736(03)14962-8",

language = "English (US)",

volume = "362",

pages = "1895--1896",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9399",

}

TY - JOUR

T1 - Effects of a SARS-associated coronavirus vaccine in monkeys

AU - Gao, Wentao

AU - Tamin, Azaibi

AU - Soloff, Adam

AU - D'Aiuto, Leonardo

AU - Nwanegbo, Edward

AU - Robbins, Paul D.

AU - Bellini, William J.

AU - Barratt-Boyes, Simon

AU - Gambotto, Andrea

N1 - Funding Information: This work was supported by National Heart Lung and Blood Institute, Program of Excellence in Gene Therapy supplement Grants U01 HL66949–01S1 to A Gambotto. The authors thank K Okada and H Sun for assistance with adenoviral preparation. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in the writing of the report.

PY - 2003/12/6

Y1 - 2003/12/6

N2 - The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.

AB - The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.

UR - https://www.scopus.com/pages/publications/0345549412

UR - https://www.scopus.com/pages/publications/0345549412#tab=citedBy

U2 - 10.1016/S0140-6736(03)14962-8

DO - 10.1016/S0140-6736(03)14962-8

M3 - Article

C2 - 14667748

AN - SCOPUS:0345549412

SN - 0140-6736

VL - 362

SP - 1895

EP - 1896

JO - Lancet

JF - Lancet

IS - 9399

ER -

Effects of a SARS-associated coronavirus vaccine in monkeys

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this